Pulmatrix (NASDAQ:PULM) Shares Pass Below 50-Day Moving Average – Here’s What Happened

Posted by Francis Steltz on May 29th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.43 and traded as low as $1.31. Pulmatrix shares last traded at $1.36, with a volume of 14,367 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

View Our Latest Analysis on Pulmatrix

Pulmatrix Stock Performance

The firm’s 50 day moving average is $1.40 and its two-hundred day moving average is $2.48. The stock has a market capitalization of $5.07 million, a PE ratio of -1.13 and a beta of 1.94.

Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP purchased a new position in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix as of its most recent SEC filing. 11.84% of the stock is owned by institutional investors.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).